Continuous Therapy in Standard- and High-Risk Newly-Diagnosed Multiple Myeloma: a Pooled Analysis of 2 Phase III Trials

Risk-adapted therapy is a common strategy in curable hematologic malignancies: standard-risk patients receive less intensive treatment, whereas high-risk patients require a more intensive approach. This model cannot be applied in multiple myeloma (MM), which is still incurable.Continuous treatment (CT) is a key strategy for MM treatment, since it improves duration of remission. However, the role of CT according to standard- or high-risk baseline prognosis remains an open question.

Source: Critical Reviews in Oncology Hematology - September 14, 2018 Category: Cancer & Oncology Authors: Mattia D ’Agostino, Lorenzo De Paoli, Concetta Conticello, Massimo Offidani, Roberto Ria, Maria Teresa Petrucci, Stefano Spada, Magda Marcatti, Lucio Catalano, Milena Gilestro, Tommasina Guglielmelli, Luca Baldini, Barbara Gamberi, Rita Rizzi, Giovanni Source Type: research